Search results for "Kidney"

showing 10 items of 1514 documents

Ferroterapia en el manejo de la anemia en la enfermedad renal crónica no en diálisis: perspectiva del grupo de anemia de la S.E.N

2021

Resumen: Este trabajo realiza una actualización sobre el manejo del déficit de hierro en pacientes con enfermedad renal crónica (ERC), ya sea con o sin anemia. Se revisan las recomendaciones de las guías para el tratamiento de la ferropenia en la ERC. Además, muestra los nuevos estudios sobre ferroterapia en pacientes con ERC, así como los nuevos conocimientos sobre el déficit férrico y su impacto en los resultados clínicos.La anemia es una complicación frecuente de la ERC y se asocia con una disminución en la calidad de vida de los pacientes, así como un aumento de la morbimortalidad. El déficit de hierro (absoluto o funcional) es frecuente en pacientes con ERC que no reciben diálisis y pu…

03 medical and health sciences0302 clinical medicineNephrologyIronIron deficiencyIron deficitChronic kidney disease030232 urology & nephrologyAnaemiaHaemoglobin030204 cardiovascular system & hematologylcsh:Diseases of the genitourinary system. Urologylcsh:RC870-923Nefrología
researchProduct

Systemic redox biomarkers and their relationship to prognostic risk markers in autosomal dominant polycystic kidney disease and IgA nephropathy.

2017

Abstract Background Oxidative stress is evident from an early stage in chronic kidney disease (CKD). Therefore, we investigated redox biomarkers in polycystic kidney disease (ADPKD) and IgA nephropathy (IGAN). Methods This is a case-control study with three groups: ADPKD (n = 54), IGAN (n = 58) and healthy controls (n = 86). The major plasma aminothiols with their redox species were examined: homocysteine (Hcy), cysteinglycine (CG), cysteine (Cys) and glutathione (GSH). The redox ratio was the ratio of reduced free and oxidized aminothiols in plasma. We investigated malonedialdehyde (MDA) and advanced oxidation protein products (AOPP), and ten single nucleotide polymorphisms of antioxidant …

0301 basic medicineAdultMaleRiskmedicine.medical_specialtyHomocysteineClinical Biochemistry030232 urology & nephrologyAutosomal dominant polycystic kidney diseaseurologic and male genital diseasesmedicine.disease_causePolymorphism Single NucleotideNephropathy03 medical and health scienceschemistry.chemical_compound0302 clinical medicineInternal medicinePolycystic kidney diseaseMedicineHumansHomocysteineGenetic Association StudiesProteinuriabusiness.industrySuperoxide DismutaseGlomerulonephritis IGAGeneral MedicineDipeptidesMiddle Agedmedicine.diseasePolycystic Kidney Autosomal DominantPrognosisOxidative Stress030104 developmental biologyEndocrinologychemistryAdvanced Oxidation Protein ProductsCase-Control StudiesDisease ProgressionFemaleGene polymorphismLipid Peroxidationmedicine.symptombusinessOxidoreductasesOxidation-ReductionOxidative stressBiomarkersKidney diseaseClinical biochemistry
researchProduct

Impact of immunosuppressive therapy on therapy-neutralizing antibodies in transplanted patients with Fabry disease.

2017

Background Inhibitory antibodies towards enzyme replacement therapy (ERT) are associated with disease progression and poor outcome in affected male patients with lysosomal disorders such as Fabry disease (FD). However, little is known about the impact of immunosuppressive therapy on ERT inhibition in these patients with FD. Methods In this retrospective study, we investigated the effect of long-term immunosuppression on ERT inhibition in male patients with FD (n = 26) receiving immunosuppressive therapy due to kidney (n = 24) or heart (n = 2) transplantation. Results No ERT-naive transplanted patient (n = 8) developed antibodies within follow-up (80 ±72 months) after ERT initiation. Seven (…

0301 basic medicineAdultMalecongenital hereditary and neonatal diseases and abnormalitiesmedicine.medical_specialtyAdolescentmedicine.medical_treatmentGastroenterology03 medical and health sciencesYoung Adult0302 clinical medicineMaintenance therapyInternal medicineInternal MedicineMedicineHumansEnzyme Replacement TherapyRetrospective StudiesKidneybusiness.industrynutritional and metabolic diseasesImmunosuppressionEnzyme replacement therapyMiddle Agedmedicine.diseaseFabry diseaseAntibodies NeutralizingKidney TransplantationTacrolimusTransplantation030104 developmental biologymedicine.anatomical_structureImmunologyPrednisoloneFabry DiseaseHeart Transplantationbusiness030217 neurology & neurosurgeryImmunosuppressive Agentsmedicine.drugJournal of internal medicine
researchProduct

SOX2 expression diminishes with ageing in several tissues in mice and humans.

2017

SOX2 (Sex-determining region Y box 2) is a transcription factor expressed in several foetal and adult tissues and its deregulated activity has been linked to chronic diseases associated with ageing. Nevertheless, the level of SOX2 expression in aged individuals at the tissue level has not previously been examined. In this work, we show that SOX2 expression decreases significantly in the brain with ageing, in both humans and rodents. The administration of resveratrol for 6 months in mice partly attenuated this reduction. We also identified an age-related decline in SOX2 mRNA and protein expression in several other organs, namely, the lung, heart, kidney, spleen and liver. Moreover, periphera…

0301 basic medicineAdultMalemedicine.medical_specialtyAgingSOX2SpleenResveratrolBiologyPeripheral blood mononuclear cellGene Expression Regulation Enzymologic03 medical and health scienceschemistry.chemical_compoundMice0302 clinical medicineSOX2stomatognathic systemInternal medicinemedicineAnimalsHumansCyclin-Dependent Kinase Inhibitor p16Aged 80 and overKidneyMessenger RNASOXB1 Transcription FactorsfungiMiddle AgedAgeing030104 developmental biologymedicine.anatomical_structureEndocrinologychemistryAgeingOrgan Specificityembryonic structuresLeukocytes MononuclearBiomarker (medicine)Femalesense organsbiological phenomena cell phenomena and immunity030217 neurology & neurosurgeryBiomarkersDevelopmental BiologyMechanisms of ageing and development
researchProduct

Urinary levels of sirtuin-1 associated with disease activity in lupus nephritis.

2017

Identifying new markers of disease flares in lupus nephritis (LN) that facilitate patient stratification and prognosis is important. Therefore, the aim of the present study was to analyze whether urinary SIRT1 expression was altered in LN and whether SIRT1 values in urine could be valuable biomarker of disease activity. In a cohort study, urinary pellets from 40 patients diagnosed with systemic lupus erythematosus (SLE) were analyzed. Clinical measures of lupus activity were assessed. The expression of SIRT1 was quantified by quantitative PCR (qRT-PCR) and immunoblot, then compared between patients with active lupus nephritis, in remission and healthy controls. Association with lupus activi…

0301 basic medicineAdultMalemedicine.medical_specialtyUrinary systemLupus nephritisGene ExpressionDiseaseUrineKidneyGastroenterologySeverity of Illness IndexPathogenesisCohort Studies03 medical and health sciencesSirtuin 1Internal medicinemedicineHumansLupus Erythematosus Systemicskin and connective tissue diseasesAgedSystemic lupus erythematosusbusiness.industryGeneral MedicineMiddle Agedmedicine.diseasePrognosisLupus Nephritis030104 developmental biologyReal-time polymerase chain reactionBiomarker (medicine)FemalebusinessBiomarkersClinical science (London, England : 1979)
researchProduct

The function of matrix metalloproteinase-9 (MMP-9) and its tissue inhibitor (TIMP-1) in several clinical conditions: Results and analysis of our surv…

2021

The goal of this research was to evaluate the plasma concentration of MMP-9 and its tissue inhibitor (TIMP-1) in different clinical conditions. It included several groups of subjects: 31 overweight subjects; 91 obese adults divided into two subgroups according to the BMI value (BMI 30–35 Kg/m2 and BMI > 35 Kg/m2); 90 subjects with metabolic syndrome (MS) divided into two subgroups (with and without diabetes mellitus); 100 subjects with preclinical carotid atherosclerosis (PCA) divided according to the number of cardiovascular risk factors and to the insulin resistance degree; 48 subjects with obstructive sleep apnoea syndrome (OSAS) divided according to the apnoea/hypopnea index (AHI); 2…

0301 basic medicineAdultmedicine.medical_specialtyPhysiologymedicine.medical_treatment030204 cardiovascular system & hematologyOverweightAdult CKD Humans metabolic syndrome Matrix Metalloproteinase 9 Metabolic Syndrome MMP-9 Obesity OSAS preclinical carotid atherosclerosis Sleep Apnea Obstructive TIMP-1 Tissue Inhibitor of Metalloproteinase-103 medical and health sciences0302 clinical medicineInsulin resistancePhysiology (medical)Diabetes mellitusInternal medicinemedicineHumansObesityDialysisMetabolic SyndromeSleep Apnea ObstructiveTissue Inhibitor of Metalloproteinase-1business.industryHematologymedicine.diseaseObesity030104 developmental biologyMatrix Metalloproteinase 9medicine.symptomMetabolic syndromeCardiology and Cardiovascular MedicinebusinessHypopneaKidney diseaseClinical hemorheology and microcirculation
researchProduct

Glucagon-like peptide-1 (GLP-1) receptor agonists and their cardiovascular benefits-The role of the GLP-1 receptor.

2021

Cardiovascular outcome trials revealed cardiovascular benefits for type 2 diabetes mellitus patients when treated with long-acting glucagon-like peptide-1 (GLP-1) receptor agonists. In the last decade, major advances were made characterising the physiological effects of GLP-1 and its action on numerous targets including brain, liver, kidney, heart and blood vessels. However, the effects of GLP-1 and receptor agonists, and the GLP-1 receptor on the cardiovascular system have not been fully elucidated. We compare results from cardiovascular outcome trials of GLP-1 receptor agonists and review pleiotropic clinical and preclinical data concerning cardiovascular protection beyond glycaemic contr…

0301 basic medicineAgonistendocrine systemmedicine.drug_classDiseasePharmacologyCardiovascular SystemGlucagon-Like Peptide-1 Receptor03 medical and health sciences0302 clinical medicineGlucagon-Like Peptide 1Diabetes mellitusMedicineHumansHypoglycemic AgentsReceptorGlucagon-like peptide 1 receptorPharmacologyKidneybusiness.industrydigestive oral and skin physiologyType 2 Diabetes Mellitusmedicine.diseaseGlucagon-like peptide-1030104 developmental biologymedicine.anatomical_structureDiabetes Mellitus Type 2Cardiovascular Diseasesbusinesshormones hormone substitutes and hormone antagonists030217 neurology & neurosurgeryBritish journal of pharmacology
researchProduct

Cardiotoxic Effects of Anti-VEGFR Tyrosine Kinase Inhibitors

2016

Angiogenesis is a key moment in tumor development and proliferation. Until recently oncologists did not know the mechanisms that were behind this phenomenon, but following the discoveries of Folkman and coworkers, they have gradually created and developed a series of drugs that act against angiogenesis by interacting with molecules belonging to the vascular endothelial growth factor (VEGFs) class and its receptors (VEGFRs) giving rise to anticancer effects. Tyrosine kinase inhibitors (TKIs) are a major class of these new anticancer agents, demonstrating high antitumor activity in a variety of "orphan" neoplasms (such as hepatocellular carcinoma, kidney cancer, sarcomas, etc.). The mechanism…

0301 basic medicineAngiogenesis; Cardio-oncology; Cardiotoxicity; Tyrosine kinase inhibitors; VEGF; VEGF pathway; Medicine (all)Settore MED/06 - Oncologia MedicaAngiogenesisTyrosine kinase inhibitorPharmacology03 medical and health scienceschemistry.chemical_compound0302 clinical medicineVEGF pathwaymedicineReceptorCardiotoxicitybusiness.industryMedicine (all)medicine.diseaseVEGFCardiotoxicityVascular endothelial growth factorAngiogenesiCardio-oncology030104 developmental biologyMechanism of actionchemistry030220 oncology & carcinogenesisHepatocellular carcinomamedicine.symptombusinessKidney cancerTyrosine kinase
researchProduct

Tenofovir-induced toxicity in renal proximal tubular epithelial cells

2017

OBJECTIVE In-vivo studies suggest that mitochondria is involved in tenofovir (TFV)-induced renal toxicity, but the underlying mechanisms are still unclear. The aim of the present study was to assess the effects of TFV and its prodrug, TFV disoproxil fumarate, on mitochondrial function and cell survival/viability in a renal proximal tubular cell line. DESIGN AND METHODS We evaluated parameters of cellular proliferation/survival (cell count, cell cycle, viability) and mitochondrial function (oxygen consumption, mitochondrial membrane potential, reactive oxygen species production) in NRK-52E cells. Intracellular TFV was measured by HPLC and expression of antioxidant genes was analysed by real-…

0301 basic medicineAnti-HIV AgentsCell Survival030106 microbiologyImmunologyCellOxidative phosphorylationMitochondrionPharmacologyCell Line03 medical and health sciencesmedicineHumansImmunology and AllergyTenofovirCell Proliferationchemistry.chemical_classificationKidneyReactive oxygen speciesCell growthEpithelial Cellsmedicine.diseaseMitochondriaMitochondrial toxicity030104 developmental biologyInfectious Diseasesmedicine.anatomical_structurechemistryIntracellularAIDS
researchProduct

In vitro effects of Origanum vulgare leaf extracts on gilthead seabream (Sparus aurata L.) leucocytes, cytotoxic, bactericidal and antioxidant activi…

2018

Abstract Origanum vulgare is a well-known medicinal plant that has been used since ancient times as an additive in foods and cosmetic preparations. The possible application of O. vulgare extracts in fish was assessed by using gilthead seabream (Sparus aurata) as a marine fish model due to its importance in aquaculture. The in vitro effects of aqueous and ethanolic leaf extracts of O. vulgare were tested in order to observe any immunostimulant, cytotoxic, bactericidal or antioxidant properties. The results showed that medium or high concentration of aqueous extracts and low concentrations of ethanolic extract, increased head kidney leucocyte activities as well as the number of SAF-1 cells. H…

0301 basic medicineAntioxidantmedicine.drug_classCell Survivalmedicine.medical_treatmentFish farmingAquatic ScienceImmunostimulantAntioxidantsCell Line03 medical and health sciencesOriganummedicineLeukocytesEnvironmental ChemistryAnimalsFood scienceCytotoxicityVibriobiologyVibrio harveyiPhotobacteriumPlant ExtractsGeneral MedicineOriganumbiology.organism_classificationHead KidneyAnimal FeedIn vitroSea BreamDietPlant Leaves030104 developmental biologyPhotobacterium damselaeFishshellfish immunology
researchProduct